Gyre Therapeutics (GYRE) EBIT (2010 - 2026)
Gyre Therapeutics (GYRE) reported EBIT of -$9.4 million for Q1 2026, down 511.57% year-over-year from $2.3 million in Q1 2025, and down 12.21% on a QoQ basis from -$8.3 million in Q4 2025.
Gyre Therapeutics (GYRE) has 17 years of EBIT data on file, last reported at -$9.4 million in Q1 2026.
- Quarterly EBIT fell 511.57% year-over-year to -$9.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$8.6 million (down 182.93% YoY) and the FY2025 annual result came in at $3.0 million, down 81.24% from the prior year.
- EBIT declined to -$9.4 million in Q1 2026 per GYRE's latest filing, from -$8.3 million in the prior quarter.
- Across five years, EBIT topped out at $51.5 million in Q2 2022 and bottomed at -$91.6 million in Q4 2023.
- The 5-year median for EBIT is $2.3 million (2025), against an average of -$2.8 million.
- The widest annual swing landed in 2022, when EBIT jumped 358.76%; it then plunged 1353.68% in 2025.
- Tracing GYRE's EBIT over 5 years: stood at -$22.5 million in 2022, then tumbled by 307.98% to -$91.6 million in 2023, then surged by 100.73% to $665000.0 in 2024, then sank by 1353.68% to -$8.3 million in 2025, then declined by 12.21% to -$9.4 million in 2026.
- Per Business Quant, the three latest GYRE EBIT figures stand at -$9.4 million (Q1 2026), -$8.3 million (Q4 2025), and $6.9 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.97 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -15.76 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 642.90 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 268.64 Mn |
| 10 | Gyre Therapeutics | 532.38 Mn | 518.25 Mn | 8.38 Mn | -9.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.36 Mn |
| Dec 31, 2025 | -8.34 Mn |
| Sep 30, 2025 | 6.93 Mn |
| Jun 30, 2025 | 2.17 Mn |
| Mar 31, 2025 | 2.27 Mn |
| Dec 31, 2024 | 665,000.00 |
| Sep 30, 2024 | 4.23 Mn |
| Jun 30, 2024 | 3.19 Mn |
| Mar 31, 2024 | 8.07 Mn |
| Dec 31, 2023 | -91.63 Mn |
| Sep 30, 2023 | 12.76 Mn |
| Jun 30, 2023 | 4.97 Mn |
| Mar 31, 2023 | 6.66 Mn |
| Dec 31, 2022 | -22.46 Mn |
| Sep 30, 2022 | -5.17 Mn |
| Jun 30, 2022 | 51.53 Mn |
| Mar 31, 2022 | -14.70 Mn |
| Dec 31, 2021 | -20.31 Mn |
| Sep 30, 2021 | -25.23 Mn |
| Jun 30, 2021 | -19.91 Mn |
| Mar 31, 2021 | -22.44 Mn |
| Dec 31, 2020 | -18.84 Mn |
| Sep 30, 2020 | -16.10 Mn |
| Jun 30, 2020 | -17.36 Mn |
| Mar 31, 2020 | -5.07 Mn |
| Dec 31, 2019 | -13.99 Mn |
| Sep 30, 2019 | -13.20 Mn |
| Jun 30, 2019 | -14.38 Mn |
| Mar 31, 2019 | -15.71 Mn |
| Dec 31, 2018 | -11.68 Mn |
| Sep 30, 2018 | -8.35 Mn |
| Jun 30, 2018 | -7.11 Mn |
| Mar 31, 2018 | -6.68 Mn |
| Dec 31, 2017 | -5.83 Mn |
| Sep 30, 2017 | -5.88 Mn |
| Jun 30, 2017 | -5.94 Mn |
| Mar 31, 2017 | -4.17 Mn |
| Dec 31, 2016 | -5.22 Mn |
| Sep 30, 2016 | -5.71 Mn |
| Jun 30, 2016 | -4.92 Mn |
| Mar 31, 2016 | -4.57 Mn |
| Dec 31, 2015 | -4.68 Mn |
| Sep 30, 2015 | -3.89 Mn |
| Jun 30, 2015 | -2.20 Mn |
| Mar 31, 2015 | -3.03 Mn |
| Dec 31, 2014 | -1.80 Mn |
| Sep 30, 2014 | -1.64 Mn |
| Jun 30, 2014 | -2.21 Mn |
| Mar 31, 2014 | -1.86 Mn |
| Dec 31, 2013 | -13.31 Mn |
| Sep 30, 2013 | -13.15 Mn |
| Jun 30, 2013 | -12.49 Mn |
| Mar 31, 2013 | -8.27 Mn |
| Dec 31, 2012 | -16.26 Mn |
| Sep 30, 2012 | -8.10 Mn |
| Jun 30, 2012 | 14.23 Mn |
| Mar 31, 2012 | 1.99 Mn |
| Dec 31, 2011 | -10.15 Mn |
| Sep 30, 2011 | -9.33 Mn |
| Jun 30, 2011 | -2.57 Mn |
| Mar 31, 2011 | 12.30 Mn |
| Dec 31, 2010 | -1.36 Mn |
| Sep 30, 2010 | 2.42 Mn |
| Jun 30, 2010 | 4.97 Mn |